At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 181 enrolled
Drug / intervention
mRNA-1647 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 When Administered to Healthy Adults
In Brief
A Phase 1 clinical trial evaluating mRNA-1647, mRNA-1443, and 1 other intervention for Cytomegalovirus Infection. Completed, enrolled 181 participants across 4 sites.
Detailed Summary
This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1647 and mRNA-1443 cytomegalovirus vaccines in healthy adults
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCytomegalovirus Infection
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedDec 2017
Primary CompletionOct 2020
TodayJul 2026
First PostedDec 22, 2017
Enrollment StartNov 13, 2017
Primary CompletionOct 28, 2020
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 8.5 years ago
Interventions
mRNA-1647biological
Escalating dose levels
mRNA-1443biological
Escalating dose levels
Placeboother
Saline